ENDP - SHORT-TERM SHORT & LONG-TERM BUY - Endo Pharma

ENDP

Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company.

The Crash: Revenue Is In Free Fall
Endo Pharmaceuticals: The Free Fall Continues
Mar. 26, 2018

Summary

Revenue from ENDP's core Generics business is in decline and other business segments appear in disarray.

Its 88B debt load is at 7.5x run-rate EBITDA. If operating income continues to slide, it could hurt ENDP's ability to service its debt.

ENDP ENDP trades at 9x EBITDA, but it is uncertain if potential legal exposures pursuant to opioids are priced in.

Sell ENDP.

This idea was discussed in more depth with members of my private investing community, Shocking The Street.

There is a war being fought over drug prices. Lawmakers have hit back at price gougers and opioid manufacturers, and Endo Pharmaceuticals (ENDP) is in the middle of it. A few months ago, I thought Endo was at an inflection point and there was a good probability it could turn things around. However, its slide continues.

What: The bottom dropped out from under shares of Endo International plc (NASDAQ:ENDP), the specialty pharma famous for selling "uncrushable" opioids and agreeing to enormous legal settlements. After management revealed disturbing revisions of its 2016 full-year estimates, the stock plummeted 41.4% last month, according to data from S&P Global Market Intelligence.

Logical? Sold because they sell opiates? Are opiated still needed/critical to US Healthcare?

NO!

BIG Consolidation period: 4 Years (2014-2018)

The First CYCLE WAVE Completed.

Now, in the middle of the SECOND WAVE (Correction)

Key Levels for Retrace: 1, 1.382, & 1.618

Look for retrace back to around $13.00 ENDP

screenshots.firefox.com/LwvODTTnZdZZNGOP/www.tradingview.com

screenshots.firefox.com/rmVEMDl6oLtj35dA/www.tradingview.com

screenshots.firefox.com/gSja4qXIhxRrAWx7/www.tradingview.com

Most Recent News:
Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law.

Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law.

Analysts at RBC Capital upgraded Endo International PLC (NASDAQ:ENDP) from Sector Perform to Outperform. Endo shares rose 2.56 percent to $16.05 in pre-market trading.


Will update.

-Stay humble America,

-AB